Pulmonx Corp cash flow statement
In fiscal 2025, Pulmonx Corp's operations generated −$32.4m of cash; it spent $452,000 on capital projects, leaving free cash flow of −$32.8m.
Cash flow statement
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −18 | −21 | −31 | −41 | −45 | −38 | −32 | −32 | −31 |
| Depreciation and amortisation | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 0 | 0 | 3 | 11 | 16 | 22 | 23 | 21 | 17 |
| Capital spending | 0 | 1 | 1 | 4 | 1 | 1 | 1 | 0 | 0 |
| Free cash flow | −19 | −21 | −32 | −45 | −46 | −38 | −33 | −33 | −31 |
| Free cash flow after stock pay | −19 | −22 | −35 | −56 | −63 | −61 | −56 | −54 | −48 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | −7 | −13 | −4 | −8 | −7 | −10 | −5 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 6 | 6 | 6 | 6 | 5 | 4 | 4 | 4 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −8 | −7 | −14 | −4 | −8 | −7 | −10 | −5 |
| Free cash flow after stock pay | −13 | −12 | −19 | −10 | −13 | −11 | −14 | −9 |
Compare with peers
- Iradimed Corp cash flow
- Sight Sciences, Inc. cash flow
- Delcath Systems, Inc. cash flow
- Tela Bio, Inc. cash flow
- PRO DEX Inc cash flow
Head to head: IRMD vs LUNGLUNG vs SGHTDCTH vs LUNG
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies